Long-term effects of benzodiazepine discontinuation among older adults: potential improvements on depressive symptoms.

IF 2.8 3区医学 Q3 GERIATRICS & GERONTOLOGY

Aging & Mental Health Pub Date : 2024-12-01 Epub Date: 2024-07-02 DOI:10.1080/13607863.2024.2372473

Arnaud Allary, Virginie Proulx-Tremblay, Claude Bélanger, Carol Hudon, Kieron O'Connor, Pasquale Roberge, Helen-Maria Vasiliadis, Caroline Desrosiers, Diana Cruz-Santiago, Sébastien Grenier

{"title":"Long-term effects of benzodiazepine discontinuation among older adults: potential improvements on depressive symptoms.","authors":"Arnaud Allary, Virginie Proulx-Tremblay, Claude Bélanger, Carol Hudon, Kieron O'Connor, Pasquale Roberge, Helen-Maria Vasiliadis, Caroline Desrosiers, Diana Cruz-Santiago, Sébastien Grenier","doi":"10.1080/13607863.2024.2372473","DOIUrl":null,"url":null,"abstract":"Objectives: To examine how change in benzodiazepine (BZD) use is linked to changes in depressive symptoms intensity, worry intensity, and sleep quality over 16 months.Method: Data come from a larger randomised controlled trial (RCT) named the 'Programme d'Aide du Succès au SEvrage (PASSE-60+)' study (NCT02281175). Seventy-three participants age 60 years and older took part in a 4-month discontinuation programme and were assessed four times over 16 months. Change in BZD use was defined as the difference in reported mg/day between two assessments. Control variables were RCT discontinuation group; BZD use at T1; and either depressive symptoms, worry intensity, or sleep quality at T1. Hierarchical multiple regressions were used to analyse data.Results: In the short term, right after the discontinuation programme, sleep quality worsened with lower BZD use. This link was no longer significant at the 3- and 12-month follow-up. In the long term, depressive symptoms lowered with lower BZD use. No change was found in worry intensity in relation to BZD use at all measurement times.Conclusion: Discontinuation may improve depressive symptoms. Our study also questions the long-term effectiveness of BZD use, since long-term discontinuation was not linked with change in worry intensity and sleep quality.","PeriodicalId":55546,"journal":{"name":"Aging & Mental Health","volume":" ","pages":"1625-1633"},"PeriodicalIF":2.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging & Mental Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13607863.2024.2372473","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To examine how change in benzodiazepine (BZD) use is linked to changes in depressive symptoms intensity, worry intensity, and sleep quality over 16 months.

Method: Data come from a larger randomised controlled trial (RCT) named the 'Programme d'Aide du Succès au SEvrage (PASSE-60+)' study (NCT02281175). Seventy-three participants age 60 years and older took part in a 4-month discontinuation programme and were assessed four times over 16 months. Change in BZD use was defined as the difference in reported mg/day between two assessments. Control variables were RCT discontinuation group; BZD use at T1; and either depressive symptoms, worry intensity, or sleep quality at T1. Hierarchical multiple regressions were used to analyse data.

Results: In the short term, right after the discontinuation programme, sleep quality worsened with lower BZD use. This link was no longer significant at the 3- and 12-month follow-up. In the long term, depressive symptoms lowered with lower BZD use. No change was found in worry intensity in relation to BZD use at all measurement times.

Conclusion: Discontinuation may improve depressive symptoms. Our study also questions the long-term effectiveness of BZD use, since long-term discontinuation was not linked with change in worry intensity and sleep quality.

查看原文本刊更多论文

老年人停用苯二氮卓类药物的长期影响：对抑郁症状的潜在改善。

目的：研究苯二氮卓（BZD）使用量的变化与抑郁症状强度、担忧强度和睡眠质量在 16 个月内的变化有何联系：研究16个月内苯二氮卓（BZD）使用量的变化如何与抑郁症状强度、担忧强度和睡眠质量的变化相关联：数据来自一项名为 "Programme d'Aide du Succès au SEvrage (PASSE-60+)"（NCT02281175）的大型随机对照试验（RCT）。73 名 60 岁及以上的参与者参加了为期 4 个月的停药计划，并在 16 个月内接受了 4 次评估。BZD使用量的变化被定义为两次评估之间报告的毫克/天的差异。对照变量包括：RCT停药组；T1时的BZD使用情况；T1时的抑郁症状、担忧强度或睡眠质量。数据分析采用层次多元回归法：结果：在短期内，即停药计划结束后，睡眠质量会随着 BZD 使用量的减少而恶化。在 3 个月和 12 个月的随访中，这种联系不再明显。从长期来看，抑郁症状随着 BZD 使用量的减少而减轻。在所有测量时间内，均未发现担忧强度与使用BZD有关：结论：停药可改善抑郁症状。我们的研究还对使用 BZD 的长期有效性提出了质疑，因为长期停用 BZD 与担忧强度和睡眠质量的变化无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Aging & Mental Health 医学-精神病学

CiteScore

7.00

自引率

2.90%

发文量

176

审稿时长

4-8 weeks

期刊介绍： Aging & Mental Health provides a leading international forum for the rapidly expanding field which investigates the relationship between the aging process and mental health. The journal addresses the mental changes associated with normal and abnormal or pathological aging, as well as the psychological and psychiatric problems of the aging population. The journal also has a strong commitment to interdisciplinary and innovative approaches that explore new topics and methods. Aging & Mental Health covers the biological, psychological and social aspects of aging as they relate to mental health. In particular it encourages an integrated approach for examining various biopsychosocial processes and etiological factors associated with psychological changes in the elderly. It also emphasizes the various strategies, therapies and services which may be directed at improving the mental health of the elderly and their families. In this way the journal promotes a strong alliance among the theoretical, experimental and applied sciences across a range of issues affecting mental health and aging. The emphasis of the journal is on rigorous quantitative, and qualitative, research and, high quality innovative studies on emerging topics.